XVIVO is a medical technology company which develops and markets solutions and systems for storage, preservation and assessment of donated organs outside the body.
Currently, more than 90 per cent of transplant clinics use PERFADEX® Plus which is used for traditional preservation of lungs. The company’s products XPS™ and STEEN Solution™ for warm perfusion have regulatory approval in all major markets. They are the first products for warm perfusion of marginal lungs to have received regulatory approval from the FDA (PMA approval). XVIVO’s Heart preservation technology is undergoing clinical trials in three contients. For abdominal organs, XVIVO’s Liver Assist and Kidney Assist are the only devices for ex vivo perfusion at temperatures ranging from hypothermic to normothermic. Kidney Assist Transport is the portable perfusion system for hypothermic preservation during transport. The device has FDA 510(k) clearence and is CE marked.
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO employs approximately 110 people at HQ in Gothenburg, Sweden, office in Lund, Sweden, Groningen, The Netherlands, its offices in North America in Denver and Philadelphia, USA and office in Shanghai, China. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO.